Lancôme Absolue Longevity MD Anticipate The Cream is a French proactive longevity skincare treatment formulated with Mitopure to target visible biological age. This rich cream is designed for skin aged 35 and under to anticipate signs of ageing before they appear.
What if you could choose your age? Discover new Absolue Longevity MD, our first proactive targeted longevity skincare solution to reverse your skin's visible biological age, at every life stage.
Choose your longevity protocol:
(Age 35 and under) Anticipate The Cream:
This new longevity cream proactively anticipates ageing signs before they appear. Formulated with Mitopure® by Timeline.
Scientifically proven to target visible biological age skin age. Mitopure® is a micronised form of Urolithin-A, proven to support skin longevity. For targeted efficacy, Mitopure® is combined with the new proprietary and unique Anticipate compound. Driven by Epigenomyl, this proprietary longevity complex fuses Eperuline, Ectoin, and Rose Pro-Xylane with Taurine to help support your skin's visible biological age, addressing cells' core integrity for preserved youth capital.
Engineered for high-precision affinity, our Second Skin Texture Technology mimics the skin's natural surface to ensure an intuitive infusion of ingredients. Characterised by its distinctive Mitopure® yellow hue, the formula integrates rapidly upon contact, reinforcing the skin barrier without weight. It leaves a refined, breathable finish and a sensation of deep, lasting replenishment, resulting in optimised skin texture¹ and -16% incoming fine lines².
Your skin's visible biological age, the only age you can reverse.
Clinical study, 94 women, 2 x daily application. Average results, visual grading. Equivalence in years of improving 6 key signs (forehead, glabellar and crow's feet wrinkles, corner of the lips wrinkles, nasolabial fold and ptosis) in 2 months of using Anticipate The Cream. Individual results will vary. ¹Clinical scoring, 76 persons after 3 months. ²Clinical scoring, 76 people after 3 months.
